Clinesian, a “boutique global CRO” recently established as a joint venture between two US-based contract research organisations (CROs), ClinicAid Research Management and Quartesian, has now forged an alliance with Advanced Clinical Research Institute (ACRI), a Phase I to IV clinical research centre also located in Southern California.

The strategic partnership will provide “a seamless integration of study conduct with full CRO services”, including project management, monitoring, quality assurance, data management, biostatistics and medical writing, the companies said.

Moreover, added Clinisean’s chief executive officer, Gary Slizgi, “our extensive expertise in Phase I and ACRI’s proven track record as a Phase I research facility will make this strategic alliance a powerful fit”.

Clinesian employs more than 50 people worldwide, with offices in the US (California and New Jersey), India and the Ukraine. The joint venture was formed in mid-July, building on a strong existing east-west coast relationship between Quartesian (headquarters in Princeton; offices in Bangalore, India and Kharkov, Ukraine) and (headquarters in Irvine, California).

The rationale is that ClinicAid provides clinical expertise in project management, monitoring and quality assurance, supplemented by Quartesian’s capabilities in data management, statistics and medical writing. The business model includes a regionally based monitoring service for rapid trial scale-up and retained full-time equivalents for offshoring data management and statistical programming.

ACRI has more than 20 years of clinical research experience, with over 1,000 trials under its belt. The Institute runs trial sites in Anaheim and Orange, California, as well as an endoscopy centre in Anaheim.